Cannabinoids and PPAR Ligands: The Future in Treatment of Polycystic Ovary Syndrome Women with Obesity and Reduced Fertility

• Published in: Cells (Basel, Switzerland) Switzerland), 2022-08, Vol.11 (16), p.2569
• Main Authors: Przybycień, Piotr, Gąsior-Perczak, Danuta, Placha, Wojciech
• Format: Article
• Language: English
• Subjects: Cannabinoids; Care and treatment; CB1R; CB2R; Cell receptors; Chemotherapy; Chronic pain; Endocannabinoid system; endocannabinoids; Glucose metabolism; Health aspects; Infertility; Insulin resistance; Ligands (Biochemistry); Lipid metabolism; Metabolic pathways; Multiple sclerosis; Nausea; Obesity; Pathophysiology; PCOS; Peroxisome proliferator-activated receptors; Polycystic ovary syndrome; PPARs; Review; Spasticity; Stein-Leventhal syndrome; Therapeutic applications; Therapeutic targets; Vomiting; Womens health
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells11162569

Cannabinoids (CBs) are used to treat chronic pain, chemotherapy-induced nausea and vomiting, and multiple sclerosis spasticity. Recently, the medicinal use of CBs has attracted increasing interest as a new therapeutic in many diseases. Data indicate a correlation between CBs and PPARs via diverse mechanisms. Both the endocannabinoid system (ECS) and peroxisome proliferator-activated receptors (PPARs) may play a significant role in PCOS and PCOS related disorders, especially in disturbances of glucose-lipid metabolism as well as in obesity and fertility. Taking into consideration the ubiquity of PCOS in the human population, it seems indispensable to search for new potential therapeutic targets for this condition. The aim of this review is to examine the relationship between metabolic disturbances and obesity in PCOS pathology. We discuss current and future therapeutic interventions for PCOS and related disorders, with emphasis on the metabolic pathways related to PCOS pathophysiology. The link between the ECS and PPARs is a promising new target for PCOS, and we examine this relationship in depth.